CLDX Celldex Corp: Long-Term Debt to Capital Coefficient

Symbol and logo of brand Celldex Corp (CLDX)

Protected by monoclonal antibody patents, Celldex Therapeutics (CLDX) possesses a significant competitive advantage driven by high R&D expenditures. The company is developing treatments for dermatitis and urticaria, expanding its presence in the immunology segment via barzolitinib. This chart illustrates that the asset's market value is fixed at 0.00. The development of targeted therapies for oncology and inflammation is being conducted in collaboration with leading clinics.

CLDX - Celldex Therapeutics Inc Long-Term Debt to Equity over the range 07/04/2022 - 10/28/2026

Comprehensive metric breakdowns and analytics for Celldex Therapeutics (CLDX)

- price and consensus price forecast:
Quote Chart Celldex Therapeutics Inc|CLDX - Analyst Consensus Forecast
- market capitalization data:
Market Value Celldex Therapeutics, Inc.|CLDX - Enterprise Value
- book capitalization data:
Book Value per Share Celldex Therapeutics|CLDX - Company Book Value|Market Value to Book Value celldex.com|CLDX - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Celldex Therapeutics|CLDX - Long-Term Debt to Capital|Short-Term Debt to Capital celldex.com|CLDX - Company Total Debt|Debt to Net Assets Ratio Celldex Therapeutics, Inc.|CLDX - Company Long-Term Debts|Short-Term Debt Volume Celldex Therapeutics
Initial company analysis:CLDX, Celldex Therapeutics Inc
Core merchandise of Celldex Therapeutics

This indicator measures the share of long-term liabilities within the equity structure, reflecting the degree of financial autonomy and reliance on external borrowing. For Celldex Therapeutics (CLDX), which invests in the development of monoclonal antibodies against cancer, a low long-term debt-to-equity ratio is critical to sustaining a prolonged R&D cycle prior to the commercialization of its drugs.

Direct competitors

Long-Term Liabilities to Equity argenx N.V.|BioNTech Group (BNTX) - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient Abivax S.A. (ABVX)|Long-Term Debt to Capital ADMA (ADMA Biologics)|protagonist-inc.com - Long-Term Debt to Capital|Long-Term Debt to Equity Immunovant (IMVT)|KNSA: Long-Term Debt to Capital Coefficient|GRFS (Grifols Group) - Long-Term Debt to Equity|Adaptive Biotechnologies Inc. (ADPT) - Long-Term Debt to Equity Ratio|AUPH (Aurinia Pharmaceuticals) - Long-Term Debt to Capital|Long-Term Debt to Capital biocryst.com (BCRX)|Vera Therapeutics (VERA) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient Dianthus Therapeutics Inc (DNTH)|Long-Term Debt to Capital PHVS|AbCellera - Ratio of Long-Term Indebtedness to Capital|TRML: Long-Term Debt to Equity|PGEN: Long-Term Debt to Equity Ratio|PHAR (Pharming Group) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Nektar Therapeutics Inc|UPB (Upstream Bio Corp) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital ZBIO|Long-Term Debt to Equity Immunome, Inc. IMNM|Long-Term Debt to Capital Ratio gossamerbio.com (GOSS)|KALV: Long-Term Debt to Capital|Long-Term Liabilities to Capital Septerna, Inc. SEPN|PVLA: Long-Term Debt to Capital|SVRA - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital RIGL|ANAB (anaptysbio.com) - Long-Term Liabilities to Capital|Long-Term Debt to Equity Astria Therapeutics, Inc.|Long-Term Debt to Equity ENGN|Long-Term Debt to Equity RAPT Therapeutics, Inc. (RAPT)|Long-Term Debt to Equity aerovatetx.com (JBIO)|ACRS - Long-Term Debt to Capital|Long-Term Debt to Capital Ratio kyvernatx.com KYTX|TLSA (Tiziana Life Sciences Ltd) - Long-Term Debt to Capital|Cabaletta Bio Inc. (CABA) - Long-Term Liabilities to Capital|Long-Term Debt to Equity Ratio Ventyx Bio|Long-Term Debt to Capital Ratio Theratechnologies, Inc|AVTX - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient eledon.com (ELDN)|Long-Term Debt to Equity Ratio Agenus Inc.|Long-Term Loans to Capital Ratio Climb Bio Inc. (CLYM)|Long-Term Debt to Capital Zura Bio Limited|Long-Term Debt to Capital Coefficient aTyr Pharmaceuticals ATYR|ADAG (Adagene Corp) - Long-Term Debt to Capital|IMA: Long-Term Liabilities to Capital|Long-Term Debt to Equity shattucklabs.com STTK|Equillium (EQ) - Long-Term Debt to Capital Coefficient|CNTB (Connect Biopharma Holdings) - Long-Term Debt to Capital|Long-Term Debt to Capital IMUX|ATRA - Long-Term Debt to Equity|Long-Term Liabilities to Equity inflarx.de (IFRX)|XFOR: Long-Term Debt to Capital|ACET - Long-Term Liabilities to Capital|Celularity Corp - Long-Term Debt to Equity Ratio|INmune Bio Corporation (INMB) - Long-Term Debt to Capital|BRNS - Long-Term Debt to Equity Ratio|kezarlifesciences.com (KZR) - Long-Term Loans to Capital Ratio|SABS: Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Akari Therapeutics PLC|Long-Term Debt to Capital ENLV (Enlivex Therapeutics)|Long-Term Debt to Equity Ratio QTTB (q32bio.com)|Long-Term Debt to Equity GOVX|Ratio of Long-Term Indebtedness to Capital edesabiotech.com EDSA|IBIO: Long-Term Debt to Capital|CARM: Long-Term Debt to Equity Ratio|XTL Biopharmaceuticals, Ltd. (XTLB) - Long-Term Debt to Equity|Bolt Biotherapeutics, Inc. (BOLT) - Long-Term Debt to Equity|Long-Term Debt to Capital HCW Biologics, Inc. (HCWB)|Long-Term Debt to Capital Ratio Aptevo (APVO)|Long-Term Debt to Equity Ratio AIM ImmunoTech AIM|Long-Term Debt to Capital Ratio ADTX (aditxt.com)|GRI Bio Corp (GRI) - Long-Term Debt to Equity|Long-Term Liabilities to Equity XORTX Corp XRTX|Long-Term Debt to Capital Vyome Holdings Inc (HIND)|REVB - Long-Term Debt to Capital Coefficient|INDP: Long-Term Debt to Capital|SCNI (Scinai Immunotherapeutics Ltd) - Long-Term Debt to Capital|CALI - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient AFMD|Long-Term Debt to Equity ALLK (Allakos Inc.)|Long-Term Debt to Equity Ratio hookipapharma.com (HOOK)|Long-Term Debt to Capital IGMS (IGM Biosciences)|ITOS - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Ocean Bio (OCEA)|TCBP - Long-Term Debt to Capital Coefficient|Third Harmonic Bio - Long-Term Debt to Capital